Study examines treatments for relieving breathing difficulties among patients with lung effusions

Malignant pleural effusion causes disabling dyspnea (breathing difficulties) in more than 1 million people worldwide annually; patients have an average life expectancy of 4 months. "There are no robust clinical data to address which of these treatments is more effective at palliating symptoms and improving quality of life," the authors write. "Indwelling pleural catheters are increasingly used as an alternative treatment to talc pleurodesis."

The randomized controlled trial compared IPC (n = 52) and talc slurry for pleurodesis (n = 54) for patients with malignant pleural effusion who were treated at 7 U.K. hospitals. Patients were screened from April 2007-February 2011 and were followed up for a year. The researchers found that there was no significant difference between groups in dyspnea in the first 42 days after intervention. Indwelling pleural catheters reduced time in the hospital but were associated with an excess of adverse events. "As such, IPCs cannot be advocated as a superior treatment to talc pleurodesis for palliation of symptoms," the authors write.

More information: JAMA, doi:10.1001/JAMA. 2012.5535

Journal reference:

Provided by JAMA and Archives Journals